Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL

NCT01809600 is registered in ClinicalTrials.gov with Gachon University Gil Medical Center as lead sponsor.

NCT NCT01809600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01809600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL
Lead sponsor
Gachon University Gil Medical Center
Phase
Observational
Overall status
Completed
Start date
February 28, 2013
Completion date
March 31, 2014
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt's lymphoma, high-grade b-cell lymphoma